LONDON, June 27, 2016 /PRNewswire/ -- Use this report to:
Analyze the cardiac biomarkers market by cerebrovascular, congestive, coronary, hypertensive, and peripheral arterial disease and the current industrial technologies for their diagnosis.
Identify overall market trends, product opportunities, emerging regional markets, merger and acquisition opportunities and insights.
Address critically important topics for analyzing and accessing a changing market dynamic, emerging players and technologies, strategies and specific disease segments.
Investigate one of the most important drivers in the in vitro diagnostics market: additional biomarkers for heart failure, including ST2, galectin-3 and others, and biomarkers for stroke such as glial fibrillary acidic protein and S100-beta.
The global cardiac biomarkers market grew to $4.9 billion in 2015 from $4.4 billion in 2014.
The market is expected to grow at a five-year compound annual growth rate (CAGR) of 12.4% from 2015 to 2020, increasing to over $8.8 billion in 2020.
North American biomarkers is the largest sector of the market.
The market is expected to grow from $2.5 billion in 2015 to $3.9 billion in 2020 at a CAGR of 9.5% for the period 2015-2020.
The APAC biomarkers market is expected to grow from $1.1 billion in 2015 to $2.5 billion in 2020 at a CAGR of 17.6% for the period 2015-2020.
STUDY GOALS AND OBJECTIVES
This report provides a comprehensive analysis of the cardiac biomarker market and its trends from 2014 through 2020. It details the history and current state of cardiovascular diseases (CVDs), background on cardiac biomarkers and the current industrial technologies for their diagnosis.
An in-depth analysis is provided of the predominant biomarkers in the market:
- Cardiac troponin (cTn) proteins (complex I and T).
- Natriuretic peptide (BNP [brain natriuretic peptide] and NT-proBNP [N-terminal pro-hormone of brain natriuretic peptide]).
- C-reactive protein (CRP).
- Creatine kinase-MB (CK-MB).
Other related topics including intellectual property, regulatory requirement, leading diagnostics companies and the competitive landscape are also discussed. The market analysis is based on biomarker, region, demographics and instrumentation platform.
REASONS FOR DOING THE STUDY
This study was conducted to offer support to companies by providing analytical information and to help them generate business strategies. Often, the ability to successfully execute business strategies hinges on how to effectively develop an effective plan with the relevant information and data.
This report investigates one of the most important drivers in the in vitro diagnostics market: the introduction of additional biomarkers for heart failure (HF), including ST2, galectin-3 and others, as well as ongoing research of biomarkers for stroke such as GFAP (glial fibrillary acidic protein) and S100-beta.
Together, they are expected to substantially contribute to the growth of the market for cardiac biomarkers over the forecast period of 2015 through 2020. This report analyzes the emerging markets by assay type, instrumentation and region. Continued growth is expected in emerging countries, driven by the growth in the practice of preventive medicine in developing regions such as China, South America and the rest of the world.
Download the full report: https://www.reportbuyer.com/product/2070047/
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
For more information:
Research Advisor at Reportbuyer.com
Tel: +44 208 816 85 48
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cardiac-biomarkers-technologies-and-global-markets-300290726.html